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53 melanoma patients (23 women, 30 men; median age: 
64 years; median tumor thickness: 1.99 mm) with known 
primary, visible lymph nodes or subcutaneous metasta-
ses proven by ultrasound and histopathology during the 
follow-up.  Results: Especially in the axilla, infraclavicular 
region and groin the metastases were not limited to the 
anatomic lymph node regions. In 5 patients (9.4%) (4 of 
them were in stage IV) lymph node metastases were not 
located in the corresponding lymph node area. 32 pa-
tients without former SLNB had a time range between 
melanoma excision and lymph node metastases of 31 
months (median), 21 patients with SLNB had 18 months 
(p  ! 0.005). In 11 patients with positive SLNB the time 
range was 17 months, in 10 patients with negative SLNB 
21 months (p  ! 0.005); in 32 patients with CLND the time 
range was 31 months and in 21 patients without CLND 
18 months (p  ! 0.005). In thinner melanomas lymph node 
metastases occurred later (p  ! 0.05).  Conclusions: After 
surgery of cutaneous melanoma, SLNB and CLND the 
lymphatic drainage can show signifi cant changes which 
should be considered in clinical and ultrasound follow-
up examinations. Especially for high-risk melanoma pa-
tients follow-up examinations should be performed at 
intervals of 3 months in the fi rst years. Patients at stage 
IV should be examined in all regional lymph node areas 
clinically and by ultrasound. 
 Copyright © 2006 S. Karger AG, Basel 
 Key Words 
 Melanoma   Sentinel lymph node biopsy   
Consecutive complete lymph node dissection
 Abstract 
 Background: Ultrasound (sonography, B-mode sonogra-
phy, ultrasonography) examination improves the sensi-
tivity in more than 25% compared to the clinical palpa-
tion, especially after surgery on the regional lymph node 
area.  Objective: To evaluate the distribution of metasta-
ses during follow-up in the draining lymph node areas 
from the scar of primary to regional lymph nodes (head 
and neck, supraclavicular, axilla, infraclavicular, groin) 
in patients with cutaneous melanoma with or without 
sentinel lymph node biopsy (SLNB) or former elective or 
consecutive complete lymph node dissection in case of 
positive sentinel lymph node (CLND).  Methods: Prospec-
tive multicenter study of the Departments of Dermatol-
ogy of the Universities of Homburg/Saar, Tübingen and 
Munich (Germany) in which the distribution of lymph 
node and subcutaneous metastases were mapped from 
the scar of primary to the lymphatic drainage region in 
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 Introduction 
 Melanoma becomes a life-threatening malignancy 
with the developing of local, regional or distant metasta-
ses  [1, 2] . Dissemination of metastases occurs in two 
thirds of these cases through the lymphatic system  [3] . 
Mostly, the regional lymph node group associated to the 
primary melanoma is involved. A relevant prognostic pa-
rameter for further recurrences and survival is the num-
ber of affected lymph nodes  [1, 4] . Therefore, especially 
high-risk melanoma patients should be examined in the 
draining lymphatic areas during the follow-up  [5] . Here-
by, the ultrasound (sonography, B-mode sonography, ul-
trasonography) examination improves the sensitivity in 
more than 25% compared to the clinical palpation, espe-
cially after surgery on the regional lymph node area  [4, 
6–9] . Ultrasound has a high diagnostic accuracy com-
pared to the clinical examination and lower fi nancial 
costs compared to computer tomography, magnetic reso-
nance tomography or positron emission tomography  [4, 
5, 8, 9] . But, to guarantee the high diagnostic accuracy 
trained users and clear defi ned regional lymph node ar-
eas, which are associated to the primary, are demanded. 
Therefore, this prospective multicenter study was per-
formed to evaluate the distribution of metastases in the 
draining lymph node areas in melanoma patients during 
the regular follow-up detected by ultrasound. 
 Patients and Methods 
 Patients 
 Between September 2002 and August 2003, a total of 53 patients 
(23 women and 30 men) were included in this prospective study by 
the Departments of Dermatology of the Universities of Homburg/
Saar (22 patients), Tübingen (18 patients) and Munich (13 patients) 
during the follow-up of melanoma patients. Only patients with 
known primary, detected metastases of lymph nodes or intransit 
area in ultrasound and proven by histopathology were included. 
Metastases could be detected either at the fi rst presentation of the 
patients or during the follow-up. Therefore, patients were included 
with or without sentinel lymph node biopsy (SLNB) or former elec-
tive or consecutive complete lymph node dissection in case of pos-
itive sentinel lymph node (CLND). In all centers patients with a 
positive SLNB received a CLND. Not included were patients with 
unknown primary melanomas of mucous membranes or organs 
other than the skin. 
 Age range of the patients was 32–88 years (mean, 60.6 years; me-
dian, 64 years). Tumor thickness range was 0.31–20.0 mm (mean 
3.22 mm; median 1.99 mm). Patients’ characteristics are listed in 
 table 1 . The regular follow-up of melanoma patients included history, 
physical examination, ultrasound of the scar, intransit and regional 
lymph node area(s)  [5] . Structures suspicious for metastases on ultra-
sound were surgically removed for histopathologic examination. 
 Methods 
 Ultrasound examinations were performed by all authors using 
real-time scanners (Homburg/Saar: Sonoline Elegra, Siemens Med-
ical Solutions, Erlangen, Germany; Tübingen: AU4 Diagnostic Ul-
trasound System, Esaote Biomedica, Neufahrn-Munich, Germany; 
Munich: SSA-340 A, Toshiba Medical Systems, Neuss, Germany) 
with a 7.5–13 MHz linear transducer.  
 In all patients, the examination covered the scar of the primary, 
its 10-cm surrounding area and the regional lymphatic basin in 
longitudinal and transverse orientation. At the neck and extremi-
ties, this area corresponds to the large blood vessels whereas at the 
trunk about 30% of melanomas have two or more different lym-
phatic drainage areas  [10–13] . At the proximal part of the extrem-
ities the tissue compartment on the lateral and medial region of the 
main vessels were also scanned. In case the melanoma was located 
at the head or neck, always both sides of the neck including the su-
praclavicular region were examined; in case the primary was lo-
cated at one of the arms, hands or fi ngers, the axilla and infracla-
Table 1. Characteristics of 53 patients
Characteristics Number  of patients (%)
Sex
Female
Male 
23 (43.4)
30 (56.6)
Tumor thickness, mm
^0.75
^0.76–1.50
^1.51–4.00
  >4.00
Unknown
5 (9.4)
11 (20.8)
25 (47.1)
11 (20.8)
1 (1.9)
Histologic subtypes
SSM
NM
LMM
ALM
Unknown
21 (39.6)
20 (37.7)
4 (7.6)
6 (11.3)
2 (3.8)
Site of the primary tumor
Head and neck
Trunk
Arm
Leg
7 (13.2)
17 (32.1)
1 (1.9)
28 (52.8)
Sentinel lymph node biopsy
Yes
No
21 (39.6)
32 (60.4)
Positiv sentinel lymph node biopsy
Yes
No
11 (52.4)
10 (47.6)
CLND
Yes
No
32 (60.4)
21 (39.6)
SSM = Superfi cial spreading melanoma; NM = nodular mela-
noma; LMM = lentiginous malignant melanoma; ALM = acrolen-
tiginous melanoma; unknown = subtype not diagnosable in histo-
pathology.
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vicular region were examined; with a melanoma at the trunk, both 
axillas, infraclavicular regions and both groins and in case the mel-
anoma was located at the thigh, calf, foot or toes, the ipsilateral 
groin was examined. 
 In every patient this procedure was performed and documented 
in horizontal and vertical planes. Ultrasound assessment of visible 
lymph nodes was fi rst based on morphologic criteria (size, shape, 
echogenicity of the center and cortex of the lymph node). The index 
according to Solbiati (ratio of maximal and minimal diameters in 
transversal and longitudinal sonographic sections) was calculated 
for every lymph node  [14] . Lymph nodes were considered as ma-
lignant at ultrasound if the following criteria were found  [15] : Sol-
biati index less than two and/or predominance of low echogenicity 
of the whole lymph node structure and/or lymph node center with 
low echogenicity and/or asymmetric regions with low echogenicity 
in the lymph node margin. 
 In the case of malignant lymph node or subcutaneous metasta-
sis in ultrasound, the exact anatomic position was indicated in a 
fi gure ( fi g. 1–3 ) for every patient.  
 The evaluation of data was performed using the statistical pack-
age SPSS 11.5.0 (SPSS, Chicago, Ill., USA) for Windows. Statistical 
testing was performed using Wilcoxon signed ranks test or Mann-
Whitney U test. In each statistical analysis, p  ! 0.05 was regarded 
as statistically signifi cant. 
 Fig. 1. Lymph node areas at the head.  a Dorsal right side.  b Dorsal 
left side.  c Ventral right side.  d Ventral left side. Grey squares in-
dicates melanoma metastases from a primary of the head. 
 Fig. 2. Lymph node areas at the axilla.  a Dorsal left side.  b Dorsal 
right side.  c Ventral right side.  d Ventral left side. Grey squares 
indicate melanoma metastases from a primary of the lower belly or 
back and black circles from a primary of the upper thorax or back, 
shoulder, arm, hand or fi ngers. 
 Fig. 3. Lymph node areas at the groin and thigh.  a Dorsal left side. 
 b Dorsal right side.  c Ventral right side.  d Ventral left side. Grey 
squares indicate melanoma metastases from a primary of the thigh, 
calf, feet or toes and black circles from a primary of the lower belly 
or back or buttocks. 
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 Results 
 The results of the location of primary and lymph node 
metastases are given in  table 2 . In 5 of 53 patients (9.4%) 
the lymph node metastases were not found in the corre-
sponding lymph node area of the primary melanoma. Pa-
tient 11 had her primary at her right foot, followed by 
metastases in her right groins; during this study a metas-
tasis at her right axilla was detected. Patient 17 had his 
melanoma at his upper right back with metastases at his 
right axilla, followed with hepatic and pulmonal metas-
tases; a metastasis was now found in his left axilla. Patient 
19 had his melanoma at his right foot, followed by pul-
monal metastases; now a metastasis was detected at his 
right groin. Patient 36 had his melanoma at his ventral 
right thigh, followed by inguinal metastases; now a me-
tastasis was found in his left axilla. In patient 44, a me-
tastasis was detected about 10 cm above the left groin 
whereas she had a melanoma at her dorsal left calf. 
 The distribution of the metastases to the head and 
neck is presented in  fi gure 1 , to the axillas and infracla-
vicular regions in  fi gure 2 , and to the groins and thighs in 
 fi gure 3 . In 6 patients (11.3%) metastases were found at 
their neck, in 17 patients (32.1%) at the axilla, in 23 pa-
tients (43.4%) at the groin, and in 7 patients (13.2%) local 
subcutaneous metastases (thorax, back, thigh and calf) 
were diagnosed. In the patients (n = 32), in which a sen-
tinel lymph node biopsy (SLNB) was not performed, the 
time range between surgery of the primary and lymph 
node metastases was 27.3–50.5 months (mean, 38.9 
months; median, 31 months); in patients with performed 
SLNB (n = 21) the time range was 15.9–30.2 months 
(mean, 23.1 months; median, 18 months) (p  ! 0.005). A 
signifi cant difference in the time range was also found in 
the group of metastatic (n = 11; 8.0–30.0 months; mean, 
19.0 months; median, 17 months) and nonmetastatic 
(n = 10; 17.1–37.9 months; mean, 27.5 months; median, 
21 months) SLNB (p  ! 0.005). 
 Finally, a signifi cant difference was found between the 
groups with (n = 32; 24.1–40.6 months; mean, 32.3 months; 
median, 31 months) and without (n = 21; 17.3–48.8 months; 
mean, 33.1 months; median, 18 months) consecutive com-
plete lymph node dissection (CNLD) (p  ! 0.005). 
 The time differences between the surgery of the pri-
mary and lymph node metastases are given in  table 3 . If 
the melanomas were classifi ed into only two groups (thin-
ner or thicker than 1.50 mm), a signifi cant difference was 
calculated (p  ! 0.05). 
Table 2. Location of primary and lymph node metastases
Patient
No.
Location 
of primary
Location
of metastasis
1 upper left back left axilla
2 forehead left left cheek
3 ventral left thigh left groin
4 upper right shoulder right axilla
5 left foot left groin
6 right buttock right groin
7 upper left shoulder left axilla
8 left shoulder left axilla
9 left big toe left groin
10 right proximal arm right axilla
11 right foot right axilla
12 ventral left thigh left groin
13 dorsal left calf left groin
14 dorsal left head left neck
15 ventral left calf left groin
16 ventral left thigh left groin
17 upper right back left axilla
18 dorsal right head right neck
19 left foot right groin
20 upper left back left axilla
21 ventral left thigh left groin
22 ventral right thigh right groin
23 ventral left calf left groin
24 dorsal central head left groin
25 big left toe left groin
26 dorsal left calf left calf
27 left foot left groin
28 dorsal right calf right groin
29 upper left thorax left thorax
30 ventral right calf right groin
31 big right toe right groin
32 ventral left calf left groin
33 ventral left thigh left thigh
34 middle left back left back
35 ventral left thigh left thigh
36 ventral right thigh left axilla
37 ventral right thorax right axilla
38 middle right belly right axilla
39 middle right belly right axilla
40 ventral left thigh left thigh
41 ventral left thigh left groin
42 right cheek right cheek
43 dorsal left calf left groin
44 dorsal left calf left groin
45 dorsal left calf left groin
46 ventral left thigh left groin
47 upper thorax right right axilla
48 right neck right neck
49 right shoulder right axilla
50 dorsal right head right neck
51 upper right thorax right axilla
52 upper right back right back
53 upper middle thorax right axilla
 Ultrasound Mapping of Lymph Node 
Metastases 
 Dermatology 2006;212:47–52 51
 Discussion 
 As far as we know, this was the fi rst prospective study 
using ultrasound for mapping the distribution of melano-
ma metastases in regional lymph node areas with or with-
out former surgery. We found a wide distribution in the 
different areas of proven metastases in histopathology ( fi g. 
1–3 ). In 8 of 53 patients (15.1%) metastases were found in 
and around the scar in the subcutaneous tissue. In the head 
and neck region metastases were found at the glandula 
parotis, on the cheek and more or less at the area of the 
great vessels. In the axillary region metastases were found 
in the axilla and in its wide surrounding. At the back this 
included the latissimus dorsi muscle and, ventrally, metas-
tases were found in the pectoral muscles and the region of 
the upper lateral belly. In the groin, a wide distribution of 
metastases was worked out from the region above the liga-
mentum inguinale to the distal area of the thigh. Also, me-
tastases were detected medially and laterally to the main 
blood vessels. Several studies worked out that more than 
25% of the lymph node metastases cannot be detected by 
palpation  [4, 8, 9] . One special explanation for this differ-
ence between clinical and ultrasound examination could 
be that the clinical examination is less extensive than the 
wide area in which metastases could be found. 
 In 5 of 53 patients (9.4%), metastases were detected in 
other lymph node regions by using ultrasound. Four of 
the 5 patients had previous metastases in the regional 
lymph nodes or even in the organs. So these patients were 
in stage IV of their disease which could explain the spread 
of metastases in further regional lymph node areas. 
 The present data could not be compared with the data 
about the distribution of sentinel lymph node biopsy 
(SLNB)  [10–13] . Normally, lymphoscintigraphy is per-
formed before surgery of the primary or at least after a 
small excision biopsy that leads to no or little change in 
lymphatic drainage. But surgery with recommended safe-
ty margins, a SLNB or even a CNLD after positive SLNB 
have a signifi cant impact on lymphatic drainage. Physi-
cians should be aware of this when they are running clin-
ical and ultrasound follow-up examinations. 
 Signifi cant differences in the time range to progression 
were found in the groups with or without sentinel lymph 
node biopsy and with positive or negative sentinel lymph 
nodes. In the case of metastatic lymph node(s), an earlier 
recurrence in the lymph node area was worked out in pa-
tients with performed SLNB and patients with positive 
SLNB. This could also be confi rmed that thicker melano-
mas had earlier lymph node metastases than thinner 
which has also been reported in the literature  [1–5] .
However, our data showed that patients with CLND 
developed lymph node metastases signifi cantly later than 
patients without CLND. One explanation could be that 
our collective was too small for analyzing this question. 
Another explanation could be that due to the CLND mi-
crometastases are not distinguishable by ultrasound. This 
hypothesis could be supported that the most of high risk 
melanoma patients had a positive SLNB and underwent 
a CLND. Probably, this collective might have a benefi t of 
the CLND  [16] . 
 In the present study, patients with CLND had longer 
disease free time concerning lymph or subcutaneous 
metastatic nodes than patients with positive or negative 
SLNB (31, 17 and 21 months, respectively). Also here 
we have to consider that our collective, especially re-
garding the correlation of affected nodes in CLND or 
SLNB and tumor thickness, was too small for analyzing 
this question. In addition, one possible explanation 
could be that by CLND micrometastases were removed 
which remained still present in patients with positive or 
negative SLNB. Studies with a larger data base could be 
able to answer this question of distribution in the sub-
groups.  
 The early detection of subcutaneous and regional 
lymph node metastases in patients with melanoma is crit-
ical for their prognosis  [1–4] . Therefore, intensive clinical 
and ultrasound examination could improve the benefi t 
for patients in the follow-up, especially for high-risk mel-
Tumor thickness Number of
patients (%)
Minimum
months
Maximum
months
Mean
months
Median
months
^0.75 mm
^0.76–1.50 mm
^1.51–4.00 mm
  >4.00 mm
Unknown
5 (9.4)
11 (20.8)
25 (47.1)
11 (20.8)
1 (1.9)
23.1
19.9
18.9
8.2
16.0
103.7
58.2
41.0
31.3
16.0
63.4
39.1
30.0
19.7
–
49.0
27.0
18.0
14.0
–
Table 3. Time differences depending on 
thickness of tumor 
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anoma. The following recommendations are proposed for 
the ultrasound examination: 
 Examination from the Scar of Primary to the Regional 
Lymph Node Area(s).  The ultrasound examination should 
start at the site of the scar of the primary melanoma, fol-
lowed by the lymphatic drainage area(s). After examina-
tion of an area of 10 cm around the scar, the transducer 
should be moved along the lymphatic vessels to the re-
gional lymphatic region in transversal orientation.  
 Examination of the Cervical Region(s). The head of 
the patient should be turned to the opposite site. First, 
the glandula parotis will be examined in two planes. Then 
the transducer will be moved to the retroauricular area. 
The cervical vessels including the surrounding tissue will 
be examined in a horizontal and a vertical plane from the 
insertion of the sternocleidomastoidal muscle to the up-
per thoracic aperture. The evaluation of the submandib-
ular and, fi nally, the supraclavicular region follows. 
 Examination of the Axillary and the Infraclavicular 
Region(s). Patients will be examined in a position with a 
120° abduction of the arm. The examination will be per-
formed in a horizontal pattern in cross-sections along the 
axillary artery, starting from lower axillary region towards 
the brachial artery and the proximal third of the upper 
arm, and to the opposite towards the subclavian artery. 
Finally, the area between the latissimus dorsi (posterior 
axillary line), the pectoral muscles (anterior axillary line) 
and the beginning of the upper arm (upper limitation) will 
be completely evaluated.  
 Examination of the Groins. The inguinal ligament, in-
guinal and femoral vessels are the leading anatomic struc-
tures for examination of this area. Following the inguinal 
ligament from the anterior superior iliac spine to the sym-
physis, the vessels will be crossed. Now the transducer 
follows the vessels in a horizontal plane 5–10 cm cranial 
of the inguinal ligament. Caudal of the inguinal ligament, 
the adductor canal will be completely examined by ultra-
sound. Lateral and medial of the femoral vessels, the up-
per third of the thigh will be scanned in two planes. 
 For patients with high-risk melanoma, clinical and ul-
trasound examination should be recommended at inter-
vals of 3 months in the fi rst 3–5 years  [5] . Weekly self-
examination should be demonstrated to the patient which 
can also lead to an earlier detection of a metastasis. Pa-
tients at stage IV should be examined in all regional lymph 
node areas clinically and with ultrasound. Although the 
nodal metastases have no signifi cant impact on overall 
patient survival in stage IV, the ultrasound could be used 
for monitoring therapies, for providing tumor material 
for vaccination in clinical studies or for planning surgical 
intervention to minimize tumor load. 
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